X‑Chem Announces Publication in Nature
WALTHAM, Mass. βApril 26, 2017 β X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative DNA-encoded library platform (DEXTM) to the discovery of the next generation of small molecule therapeutics, announced today a publication in Nature. The article, co-authored by scientists from AstraZeneca Inc. and Heptares, Inc., describes the crystal structure of protease-activated receptor 2 (PAR2) complexed with an antagonist that competes with the tethered natural ligand, and a second antagonist that binds to a hitherto unknown allosteric site on the seven transmembrane-domain receptor.
X‑Chem Announces Achievement of Milestone In Orexia Collaboration
Waltham, Mass β July 22, 2020 β X-Chem, Inc. (X-Chem), the global leader in DNA-encoded small molecule library screening and drug discovery, announced today that it has met a key development milestone in its collaboration with Orexia Limited (Orexia), a company focused on developing orexin positive modulators using unique structure based drug design capabilities.
ReadiDEL
Ready-to-Use DNA-Encoded Chemical Libraries for DEL Screening in Your Laboratory X-Chemβs ReadiDEL allows you to instantly bolster your existing (or...
DELcore
DELcore Delivers the Full Power of DNA-Encoded Library (DEL) Technology DELcore delivers a full service hit discovery solution with the...
Inside Sales Specialist
The Opportunity: We are seeking an Inside Sales Specialist to be located remotely in the U.S. The Sales Specialist is...
X‑Chemβs New AI-Powered Ecosystem to Accelerate Drug Discovery
WALTHAM, Mass.; April 19, 2022 (Business Wire)Β βΒ X-Chem, the leader of DNA-encoded library (DEL) technology and artificial intelligence (AI) for small...
Almirall and X‑Chem Announce Dermatology-Focused Drug Discovery Collaboration
WALTHAM, Mass. β December 12, 2018 - X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, announced today a drug discovery partnership with Almirall, S.A. (Almirall) to discover lead compounds for innovative and challenging targets with dermatology applications.